학술논문
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis
Document Type
Abstract
Author
Source
In Blood 13 November 2019 134 Supplement 1:3183-3183
Subject
Language
ISSN
0006-4971